Sentien Announces Active IND for SBI-101 in Patients with Acute Kidney Injury
At the Stem Cell Summit on 4/7, Sentien CEO Brian Miller announced that the company’s investigational new drug (IND) application for SBI-101 for the treatment of adult patients with acute [...]
Sentien Biotechnologies Featured on Front Page of Medical Device Daily™
Sentien Biotechnologies was featured on the front page of Medical Device Daily™ on April 7, 2017. In the article, Sentien CEO Brian Miller discusses the company’s recent $12M Series [...]
Sentien CEO Brian Miller Featured on Front Page of BioWorld™ Today
Sentien Biotechnologies CEO Brian Miller was featured on the front page of BioWorld™ Today on September 15, 2016. Mr. Miller participated on a Biopharm America panel discussing “How [...]
